[Form 4] AMGEN INC Insider Trading Activity

Rhea-AI Filing Summary

Amgen Inc. (AMGN) senior vice president and chief compliance officer Nancy A. Grygiel reported option exercises and related stock sales. On 11/20/2025, she exercised options to buy 1,500 shares of common stock at $177.46 per share and 1,639 shares at $162.60 per share, then sold 1,500 shares and 1,639 shares of common stock at an average price of $337.2625 per share.

After these transactions, she directly beneficially owned 7,225 shares of Amgen common stock, which include 96 dividend equivalent units tied to unvested RSUs, and also held 104.6847 shares through the company 401(k) plan’s stock fund. She continued to hold 1,970 nonqualified stock options from the 04/27/2020 grant, while the 05/01/2019 option grant was fully exercised.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grygiel Nancy A.

(Last) (First) (Middle)

ONE AMGEN CENTER DRIVE

(Street)

THOUSAND OAKS CA 91320

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMGEN INC [ AMGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CCO

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		M		1,500	A	$177.46	8,725	D
Common Stock	11/20/2025		S		1,500	D	$337.2625(1)	7,225	D
Common Stock	11/20/2025		M		1,639	A	$162.6	8,864	D
Common Stock	11/20/2025		S		1,639	D	$337.2625(1)	7,225(2)	D
Common Stock								104.6847(3)	I	401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Nqso (Right to Buy)	$177.46	11/20/2025		M			1,500	04/27/2020	04/27/2028	Common Stock	1,500	$0	1,970	D
Nqso (Right to Buy)	$162.6	11/20/2025		M			1,639	05/01/2019	05/01/2027	Common Stock	1,639	$0	0	D

Explanation of Responses:

1. The price reported is an average price. The prices ranged from $337.17 to $337.69 per share. Full information regarding the number of shares purchased at each separate price within the range is available upon request by the SEC staff, the issuer or a security holder of the issuer.

2. These shares include 96 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

3. These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.

	/s/ Nancy A. Grygiel	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Amgen (AMGN) report in this Form 4?

The filing reports that Nancy A. Grygiel, Amgen’s senior vice president and chief compliance officer, exercised stock options and sold Amgen common shares on 11/20/2025.

How many Amgen (AMGN) shares did the insider exercise and sell?

She exercised options for 1,500 shares at $177.46 and 1,639 shares at $162.60, then sold 1,500 and 1,639 shares of common stock on the same date.

At what prices were the Amgen (AMGN) shares sold in this Form 4?

The reported sale price is an average of $337.2625 per share, with individual sale prices ranging from $337.17 to $337.69 per share.

How many Amgen (AMGN) shares does the reporting person own after the transactions?

Following the transactions, she directly beneficially owned 7,225 shares of Amgen common stock and held an additional 104.6847 shares through the company’s 401(k) plan stock fund.

What stock options remain for the Amgen (AMGN) insider after these transactions?

After exercising 1,500 options from the 04/27/2020 grant, she held 1,970 nonqualified stock options at a $177.46 exercise price. The 05/01/2019 grant at $162.60 was fully exercised, leaving 0 options from that grant.

What are the Dividend Equivalents (DEs) mentioned in the Amgen (AMGN) Form 4?

The 7,225 directly owned shares include 96 Dividend Equivalents (DEs), which are credited to unvested RSUs and paid out in Amgen common stock on a one-to-one basis according to the RSU vesting schedule.